Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hamburg Says Generic Drug Reviews Would Slow In Wake Of GOP-Backed Budget Cuts

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA commissioner predicts poor outlook for medical product review if agency loses appropriations in fiscal 2011 and 2012.
Advertisement

Related Content

FDA Could Face 13% Funding Cut Under House FY '12 Appropriations Bill
FDA Could Face 13% Funding Cut Under House FY '12 Appropriations Bill
Pharma Industry "Well Positioned" In Current Budget Debate, Avalere's Mendelson Suggests
Pharma Industry "Well Positioned" In Current Budget Debate, Avalere's Mendelson Suggests
Generic User Fees Have Four-Month Negotiating Window As Differences Narrow
Generic User Fees Have Four-Month Negotiating Window As Differences Narrow
Medical Product Safety Program Grows To $1.4 Billion In Proposed FDA FY '12 Budget
FDA Should Look Through IIRIS To Improve Science, Panel Says; Funding Is Worry

Topics

Advertisement
UsernamePublicRestriction

Register

PS071944

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel